Carvana (CVNA) Delivers First Quarterly Profit to Smash Estimates, Shares Surge as Firms Hike PTs Following a 'Milestone Quarter'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Carvana (CVNA) PT Raised to $400 at Needham & Company
August 9, 2021 7:18 AM EDTNeedham & Company analyst Chris Pierce raised the price target on Carvana (NYSE: CVNA) to $400.00 (from $325.00) while maintaining a Buy rating.
The analyst commented, "Another installment of this franchise delivers. CVNA beat handily on 2Q revenues and EBITDA, while reporting their first... More
Carvana (CVNA) PT Raised to $405 at Wells Fargo
August 6, 2021 6:42 AM EDTWells Fargo analyst Zachary Fadem raised the price target on Carvana (NYSE: CVNA) to $405.00 (from $385.00) while maintaining a Overweight rating.... More
Carvana (CVNA) PT Raised to $420 at BofA Securities
August 6, 2021 6:34 AM EDTBofA Securities analyst Nat Schindler raised the price target on Carvana (NYSE: CVNA) to $420.00 (from $375.00) while maintaining a Buy rating.
... MoreCarvana (CVNA) PT Raised to $410 at KeyBanc
August 6, 2021 5:21 AM EDTKeyBanc analyst Edward Yruma raised the price target on Carvana (NYSE: CVNA) to $410.00 (from $360.00) while maintaining a Overweight rating.... More
After-Hours Stock Movers 08/05: (GRPN) (CSOD) (CVNA) Higher; (DRNA) (ZNGA) (NVAX) Lower (more...)
August 5, 2021 6:19 PM EDTAfter-Hours Movers
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) 25.5% LOWER; announced positive top-line results from the Companys PHYOX2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. Nedosiran is Dicernas lead GalXC RNAi therapeutic candidate and is designed to inhibit the hepatic lactate dehydrogenase (LDH) enzyme an enzyme that catalyzes the final step in the glyoxylate metabolism pathway that can lead to oxalate overproduction in patients with PH. The... More
Carvana Co. (CVNA) Tops Q2 EPS by 67c, Sales Easily Beat
August 5, 2021 4:18 PM EDTCarvana Co. (NYSE: CVNA) reported Q2 EPS of $0.26, $0.67 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.34 billion versus the consensus estimate of $2.44 billion.
This was a landmark quarter for Carvana. We delivered over 100,000 cars in the... More
